Effects of E-Tonus in Moderate Parkinson's Disease (ETMOPARK)
A Randomized, Double-blind, Sham-controlled, Crossover, Pilot Clinical Investigation, Evaluating the Short-term Effects of E-Tonus, a Wearable Electromagnetic Device, on Motor Symptoms in Adult Participants With Moderate Parkinson's Disease
The goal of this clinical trial is to evaluate the short-term effect of E-Tonus, a wrist-worn device that gives off a low-intensity pulsed electromagnetic field, on functional mobility in adults with moderate Parkinson's disease. It will also learn about the short-term safety profile of E-Tonus.
研究概览
地位
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Senior Clinical Project Manager
- 电话号码:+33624358886
- 邮箱:clinical@brainandmind.fr
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Adults aged 50-75 years;
- Parkinson's disease (MDS diagnostic criteria)Hoehn & Yahr stage II to II.5 confirmed in the ON medication state;
- At least one of the following MDS-UPDRS criteria must be met, reflecting the presence of clinically meaningful gait or balance impairment but still able to walk unaided:
- MDS-UPDRS Gait (item 3.10) score = 2, OR
- Freezing of gait (item 3.11) score ranging from 1 to 2, OR
- Postural instability (item 3.12) score ranging from 1 to 2, OR
- Walking & Balance (item 2.12) score = 2, OR
- Freezing (item 2.13) score ranging from 1 to 2;
- Stable dopaminergic therapy ≥4 weeks;
- Predictable ON-state duration ≥2 consecutive hours.
Exclusion Criteria:
- Severe axial motor impairment (pre-specified items rated 3 or 4) or investigator-judged fall/safety risk;
- Pregnancy;
- Electromagnetic hypersensitivity;
- Postural hypotension, musculoskeletal, or vestibular disorders affecting balance;
- Uncontrolled cardiac, pulmonary, major neurological, or metabolic disease;
- Cognitive impairment (MoCA ≤22);
- Implanted active medical device (e.g., DBS, pacemaker) or metal implant/tattoo at the wrist application site;
- History of radial nerve injury on the device-bearing arm;
- Legally protected vulnerable adults.
学习计划
研究是如何设计的?
设计细节
- 主要用途:支持治疗
- 分配:随机化
- 介入模型:交叉作业
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Active E-Tonus
Participants wear E-Tonus on the wrist in the active condition, emitting low-frequency, low-intensity pulsed electromagnetic field stimulation, for approximately 30 minutes. In this crossover study, all participants receive both the active and sham conditions during a single study visit, in a randomized order, separated by a 30-minute washout period. Assessments are performed in the ON medication state. |
Personal, portable, wrist-worn, non-invasive Class IIa electromagnetic stimulation device manufactured by A.F. Genese. It emits a low-frequency, low-intensity pulsed electromagnetic field with a controlled pulse width, delivering peripheral transcutaneous stimulation at the wrist. Used once, for approximately 30 minutes, during a single study visit, in addition to the participant's usual Parkinson's disease medication. The same wrist-worn device in a sham configuration that emits no electromagnetic field. It is visually and physically indistinguishable from the active device, so that participants and investigators remain blinded. Used once, for approximately 30 minutes, during a single study visit. |
|
假比较器:Sham E-Tonus
Participants wear E-Tonus on the wrist in the sham condition, with no stimulation emitted, for approximately 30 minutes. The sham device is visually and physically indistinguishable from the active device. In this crossover study, all participants receive both the active and sham conditions during a single study visit, in a randomized order, separated by a 30-minute washout period. Assessments are performed in the ON medication state. |
Personal, portable, wrist-worn, non-invasive Class IIa electromagnetic stimulation device manufactured by A.F. Genese. It emits a low-frequency, low-intensity pulsed electromagnetic field with a controlled pulse width, delivering peripheral transcutaneous stimulation at the wrist. Used once, for approximately 30 minutes, during a single study visit, in addition to the participant's usual Parkinson's disease medication. The same wrist-worn device in a sham configuration that emits no electromagnetic field. It is visually and physically indistinguishable from the active device, so that participants and investigators remain blinded. Used once, for approximately 30 minutes, during a single study visit. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in instrumented Timed Up-and-Go (iTUG) 7-meter total task time: active vs. sham E-Tonus
大体时间:Baseline (before each device condition) and end-of-period (after approximately 30 minutes of device use), for each of the 2 device conditions within a single study visit (Day 1)
|
The iTUG test measures the time (in seconds) a participant needs to stand up from a chair, walk 7 meters, turn around, walk back and sit down again, from the start of the sit-to-stand transition to the end of the stand-to-sit transition. It is instrumented with an accelerometer. Two trials are performed at each time point and averaged. For each device condition (active and sham), the change from baseline to end-of-period is calculated. The outcome is the difference between active and sham conditions in this change. A greater reduction in time indicates better functional mobility. |
Baseline (before each device condition) and end-of-period (after approximately 30 minutes of device use), for each of the 2 device conditions within a single study visit (Day 1)
|
|
Incidence, severity, seriousness and relatedness of adverse events (AEs) and adverse device effects (ADEs)
大体时间:From the start of the first device application (Day 1) through 48 hours after the last device application
|
Number of participants with adverse events and adverse device effects, described by severity (mild, moderate, severe), seriousness (serious or non-serious) and relationship to the device as assessed by the investigator, by device condition (active and sham). |
From the start of the first device application (Day 1) through 48 hours after the last device application
|
合作者和调查者
调查人员
- 首席研究员:David DEVOS, Professor Neurologist、Service de Neurologie B : Neurologie vasculaire CHU de Lille - Hôpital Roger Salengro rue Emile Laine 59000 LILLE
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- BM2601-AFGE01
- IDRCB N° 2026-A01795-46 (其他标识符:ANSM (French National Agency for Medicines and Health Products Safety))
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
There is no plan to share individual participant data. This is a small pilot investigation (40 participants), and the data are collected under French and European data protection regulations (GDPR), with participant consent limited to the purposes of this study. Aggregate results will be made available through scientific publication.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.